

02

March • April  
2026

# EuroLab News

THE EFLM BI-MONTHLY NEWSLETTER

## THE STRATEGIC PLAN OF EFLM

Strategy of Laboratory Medicine:  
the EFLM Vision 2026-2027

VERSION 5 – 17-11-2025



*Leading Precision*

*Empowering Diagnostics*

*Advancing Patient-Centered Innovation*

*Shaping the Future of Laboratory Medicine*

**Editorial Information**

Newsletter Editor: Dr. Harjit Pal Bhattoa, Faculty of Medicine,  
Dep of Laboratory Medicine, University of Debrecen Hungary

**EFLM Executive Board:**

T. Zima, M. Plebani, D. Gruson, S. Jovicic, M.F. Bauer,  
A. Coskun, A. Stavelin

# Foreword

This March–April 2026 issue of EFLM EuroLabNews reflects a strategically pivotal moment for the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), characterized by forward planning, institutional continuity, and strengthened international engagement.

At the forefront is the formal introduction of the **EFLM Strategic Plan 2026–2027**, presented by President Tomas Zima. Developed through a highly collaborative process involving past, current, and incoming leadership, the plan articulates a unified vision for advancing laboratory medicine across Europe. It emphasizes innovation, harmonisation of practices, education, and the strengthening of global partnerships, positioning EFLM as a leading voice in shaping the future of diagnostic medicine. The Executive Board section further highlights EFLM’s expanding global footprint. Notably, representation at the **International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)** Executive Board underscores Europe’s growing influence in international decision-making. Additional reports describe EFLM’s participation in national congresses, exemplifying active engagement with regional professional communities and reinforcing cross-border collaboration. Organizational development is another central theme. Updates from the EFLM Office include calls for vacancies and insights from the 2025 Annual Report, reflecting a commitment to transparency, renewal, and member participation. The “Changing of the Guard” segment documents leadership transitions within national societies, illustrating both continuity and generational renewal within the profession. Scientific advancement is prominently showcased through contributions from EFLM Functional Units. Reports on **research grant outcomes**, harmonisation initiatives, and activities of technical committees—such as those focused on biological variation and standardization—demonstrate ongoing efforts to improve analytical quality, comparability of results, and clinical relevance of laboratory data. These initiatives remain foundational to enhancing patient care and evidence-based medicine. Education and professional development remain integral to EFLM’s mission. The issue summarizes a series of on-demand webinars addressing contemporary diagnostic challenges and highlights a robust schedule of upcoming educational events. Particular attention is given to the **EFLM Strategic Conference in Prague 2026**, anticipated as a key forum for interdisciplinary dialogue and strategic alignment, as well as early visibility for **EuroMedLab 2027**, reinforcing long-term planning and community engagement.

Finally, the newsletter situates EFLM activities within a broader international and temporal context through IFCC updates and a comprehensive calendar



Reported by **Harjit Pal Bhattoa**,  
Editor EFLM EuroLabNews

of events held under EFLM auspices. Together, these elements underscore a highly coordinated, dynamic, and outward-looking professional community.

In summary, this issue portrays a federation that is not only consolidating its internal structures and scientific mission but also actively shaping the future landscape of laboratory medicine through strategic vision, international collaboration, and sustained investment in professional excellence.

## Contents

The EFLM Executive Board Informs

2

EFLM Office informs

7

Changing of the guard in EFLM National Societies

7

News from the EFLM Functional Units

8

EFLM Committee “Green & Sustainable Labs”

13

Young Scientists Corner

15

Past EFLM Events

16

Upcoming EFLM Events

17

IFCC News

20

Calendar of EFLM events and events under EFLM auspices

21

## Highlights



## THE EFLM EXECUTIVE BOARD INFORMS

# Strategy of Laboratory Medicine: EFLM Vision 2026-2027

Reported by **Tomas Zima**, EFLM President

On behalf of the Executive Board, I am proud to announce the official adoption of the new EFLM Strategic Plan for 2026-2027: a forward-looking framework that will guide our Federation in the coming years.

[Click here to download it.](#)

This Strategic Plan is the result of a truly collaborative and inclusive process. It has been jointly prepared by three EFLM Presidents: Past President Prof. Mario Plebani, current President Prof. Tomas Zima and President-Elect Prof. Damien Gruson, working in close concert with the Executive Boards of 2025 and 2026, the Chairs of the EFLM Functional Units, and the representatives of our National Societies.

This shared effort reflects global healthcare trends, rapid technological evolution, and the expanding role of laboratory professionals in modern medicine. **Our ambition is clear: to position laboratory medicine as a leader in precision diagnostics, digital healthcare transformation, and integrated diagnostics, ensuring timely, accurate, and cost-effective medical testing that measurably improves patient outcomes.**

**EFLM reaffirms that every innovation in laboratory medicine must ultimately serve the patient.** We are committed to ensuring equitable access to high-quality diagnostics, strengthening patient understanding, and reinforcing trust in laboratory-generated data. In a world profoundly reshaped by technological, economic, and geopolitical forces, EFLM must act both as a scientific authority and as a societal compass, guiding the transformation of diagnostics into patient-centered, data-driven and resilient care models.

For the first time, the EFLM Strategic Plan has also been published in the scientific journal *Clinical Chemistry and Laboratory Medicine* as "[Strategy of Laboratory Medicine - EFLM Vision](#)" (*Clin Chem Lab Med.* 2025;64:582–585), further highlighting the importance and visibility of EFLM's strategic direction for Laboratory Medicine



### The Strategic Direction

A core objective of this strategy is to fully integrate the clinical laboratory into healthcare systems and clinical pathways. We will promote value-based laboratory medicine, introducing a value-based score to objectively assess quality and strengthen benchmarking and stakeholder visibility. We will advance integrated diagnostic pathways that combine laboratory, pathology, imaging, and clinical data, while supporting the sustainable adoption of advanced diagnostics — including omics technologies and AI-driven digital solutions.

Harmonization remains essential. We will further align measurement units, reference intervals, and decision limits for clinically impactful tests, while promoting personalized reference intervals, reference change values, and high-quality interpretative comments to improve clinical decision-making. In parallel, we will ensure the ethical and effective deployment of artificial intelligence and modernize education through an updated EFLM Syllabus and AI-enhanced learning tools.

Partnership and advocacy are central to our approach. We will strengthen collaboration with scientific organizations, public health institutions, regulatory bodies, and European institutions, reinforcing EFLM's leadership role in the European health ecosystem. A dedicated EFLM functional unit will monitor relevant legislation and enhance dialogue with EU authorities. Cooperation with IVD manufacturers, including engagement with MedTech Europe, will be further deepened to support innovation and regulatory alignment.

## Our Four Strategic Priorities

### 1. Advancing Value-Based Laboratory Medicine – Precision, Personalization & Clinical Integration

We will promote precision diagnostics, AI-assisted decision support, appropriate test utilization, accreditation under international standards such as ISO 15189, sustainability in laboratory operations, and preparedness for global health threats. Transitioning from volume-based to value-based testing will ensure that laboratory medicine demonstrably enhances patient care.

### 2. Strengthening Education, Cooperation and Promotion

We will modernize education, empower early-career professionals, enhance interdisciplinary collaboration, and create innovative communication platforms to reach clinicians, policymakers, and the public. We will reinforce synergies with international and regional partners while improving both internal and external communication within the EFLM ecosystem.

### 3. Advocacy – Shaping European Health Policy for Laboratory Medicine

EFLM will actively contribute to European health policy discussions, including major initiatives such as the European Health Data Space (EHDS) and AI-related regulations. We will advocate for equitable access to advanced diagnostics, reduce regional disparities, and position laboratory medicine as a key pillar of chronic disease management, prevention, and integrated care pathways.

### 4. Data Structuring and Interoperability – Enabling Intelligent and Sustainable Health Systems

We will promote structured laboratory data, interoperability with electronic health records, federated cross-border data infrastructures, and harmonized principles for AI model training and validation. Secure, reliable, and transferable laboratory data will become a central driver of research, public health monitoring, and intelligent healthcare systems.

## Looking Ahead

In summary, EFLM will continue its essential mission: to place the patient at the heart of every innovation in laboratory medicine, to strengthen the link between science, technology, and humanity, and to promote a European laboratory model defined by excellence, ethics, and sustainability.

By guiding the transformation of laboratory medicine toward an integrated, connected, and predictive approach, EFLM contributes to shaping a future where health is more accessible, personalized, and resilient to technological, economic, and geopolitical change.

In order to translate strategy into action, each issue of this newsletter will focus on concrete action plans proposed by the various EFLM Functional Units. Through these practical initiatives, we will demonstrate measurable progress and clearly illustrate our direction toward the strategic objectives we have set together.

Prof. Tomas Zima  
President, EFLM



# All-in-one Station

Reconfigure Your Lab Space

**NEW**



## SATLARS™ mini-T8

Laboratory Automation System



Centrifugation



Decapping & recapping



Sample storage



Auto-QC



Serum quality assessment



Sample input & output



[www.snibe.com](http://www.snibe.com)

**ADLM** Association for  
Diagnostics & Laboratory Medicine™

Snibe Booth: **3814**

# EFLM Symposium at the National Congress of the Azerbaijan Society of Clinical Laboratory Specialists

Reported by **Tomas Zima**, EFLM President

The European Federation of Clinical Chemistry and Laboratory Medicine has been invited to organize a dedicated symposium at the National Congress of the Azerbaijan Society of Clinical Laboratory Specialists. The symposium, entitled "New Trends in Laboratory Medicine", will take place on 1 May 2026 in Baku.

This invitation represents an important recognition of EFLM's role in promoting scientific collaboration and advancing laboratory medicine at the international level.

The symposium will include two scientific sessions featuring internationally recognized experts.



## SESSION

# 1

Chairs: Prof. Dr. Tomas Zima, Prof. Dr. Dildar Konukoglu

- **Modern cancer diagnostics: The Role of Clinical Laboratory in Precision Oncology**  
Prof. Dr. Tomas Zima
- **Cardiac Troponin T and I: Differences in Clinical Significance and Analytical Challenges**  
Prof. Dr. Karl Lackner
- **Integrative Diagnostics in Neurodegenerative Diseases**  
Prof. Dr. Sylvain Lehmann

## SESSION

# 2

Chairs: Prof. Dr. Mario Plebani, Spec. Dr. Nigar Afandiyeva

- **Same Test, Different Numbers: Challenges in Global Harmonization of Lab Results**  
Prof. Dr. Mario Plebani
- **Emerging Diagnostic Trends and Biomarker Strategies in Laboratory Endocrinology**  
Prof. Dr. Damien Gruson

The symposium will provide an excellent opportunity to discuss new trends in laboratory medicine, including precision oncology diagnostics, cardiovascular biomarkers, integrative approaches to neurodegenerative diseases and the challenges of global harmonization of laboratory results. This invitation highlights once again the growing international recognition of EFLM as a leading scientific organization in the field of laboratory medicine. By contributing its expertise and bringing together internationally renowned speakers, EFLM continues to play a key role in fostering scientific collaboration, sharing knowledge across borders, and advancing the development and impact of laboratory medicine worldwide.

# EFLM President elected as representative for Europe to the IFCC Executive Board

Reported by **Snezana Jovicic**, EFLM Executive Board Secretary

We are pleased to announce that the EFLM President, Prof. Tomas Zima, has been elected as the EFLM representative on the IFCC Executive Board for the current year.

Following the decision of the IFCC Council at the end of 2025, Prof. Zima will also continue to serve in this role for the upcoming three-year term. His mandate on the IFCC Executive Board will therefore run until 31 December 2029.

This appointment reinforces the active role of EFLM within the international scientific community and strengthens the collaboration between EFLM and IFCC in promoting high standards, innovation, and professional development in laboratory medicine worldwide.



# Are you concerned about false potassium results? Register for our webinar and learn more about causes and mitigation strategies.

## ERRONEOUS POTASSIUM RESULTS: preanalytical causes, detection, and corrective actions.

False potassium results remain a significant challenge in clinical diagnostics. Register for our webinar, you can now access the full session on-demand. Join **Dr. Kathrin Schlueter (BD Medical Affairs Manager EMEA)** as she explores critical preanalytical causes and provides practical corrective actions to ensure diagnostic accuracy.



**Dr. Kathrin Schlueter**  
BD Medical Affairs Manager EMEA

Now available to stream  
at your convenience.

Watch the on-demand webinar



Scan to  
watch  
on mobile

---

## EFLM OFFICE INFORMS

### Call for Vacancies: new open positions are available in EFLM Committees!

Reported by **Alessia Carere**, EFLM Office

---

We are delighted to inform you that the new EFLM Functional Unit on “Endocrine Laboratory Medicine” has recently been established within the EFLM Division “Science – Value-based Laboratory Medicine”.

This new Committee is chaired by Prof Dr Annemieke Heijboer and aims to facilitate collaboration and knowledge exchange among European specialists in endocrine laboratory medicine, for example by providing expert input for guideline development, standardization and educational initiatives.

We are now calling for nominations for:

- 3 Full Members
- 1 Young Scientist Member (to be less than 40y of age as of 1st January 2026)

Mark in your agenda the deadline of **April 15** and do not miss the opportunity to actively participate in the EFLM community.

We hope to receive many expressions of interests from EFLM National Societies!

We warmly invite you to visit the dedicated page to obtain detailed information: <https://www.eflm.eu/site/EFLM-open-positions>

*Click on the link above to know more about the requirements and the evaluation procedure. The term of office will be for 2 years. The position could be renewable for other two more terms if the work for the Committee is deemed essential at that time. The work is mainly conducted by e-mail and teleconferencing, the Committee usually meets once per year. Procedure for applications: Each National Society FULL Member in good standing with the membership fee can submit one nomination per each indicated position through the attached nomination form. A brief plan of the applicant’s contribution to the aims and objectives of the functional unit must be indicated in the form. Together with the form, a short CV should also be submitted underlining the qualifications and prior experience in the relevant area. Candidates must be officially nominated by their National Society through a formal letter of support. As per the EFLM Transparency Policy, all received nominations and reasons for the successful one will be made available to all those National Societies who submitted a nomination specifying also the criteria used during the evaluation process. EFLM Affiliate Members may only nominate Corresponding Members, while Corporate Members are entitled to nominate Experts/Consultants. Interested parties are invited to contact the EFLM Office for further information.*



We are happy to inform you that the EFLM Annual report for 2025 is now available!

---

## Changing of the Guard in EFLM National Societies

Reported by the EFLM Office

---

A warm welcome to the incoming National Society officers and sincere thanks to the outgoing EFLM National Representatives and National Society Presidents for their support of EFLM activities during their terms of office.

### Société Française de Biologie Clinique (SFBC)

Jean-Louis Beaudeau (Faculté de Pharmacie de Paris, Université Paris Cité; service de biochimie métabolique, Hôpital Pitié-Salpêtrière, Paris, France) is the new President of the Société Française de Biologie Clinique. We are also pleased to inform you that Katell Peoc’h, former President of the society will cover the role of EFLM National Representative.

### Swiss Society of Clinical Chemistry

Daniel Müller (Institut für Labormedizin soH, Solothurner Spitäler, Olten, Switzerland) is the new President of the Swiss Society of Clinical Chemistry, replacing Pierre-Alain Binz.

### Spanish Society of Laboratory Medicine (SEMEDLAB)

Pastora Rodríguez (Complejo Hospitalario Universitario A Coruña – CHUAC, Spain) is the new President of the Spanish Society of Laboratory Medicine, replacing Antonio Buño Soto.

### German Society of Clinical Chemistry and Laboratory Medicine

Mariam Klouche (LADR GmbH Medizinisches Versorgungszentrum, Bremen, Germany) is the new President of the German Society of Clinical Chemistry and Laboratory Medicine, replacing Harald Renz.

---

## NEWS FROM THE EFLM FUNCTIONAL UNITS

### EFLM RESEARCH GRANT

## Winners of the EFLM Research Grant 2026

Reported by **Dalius Vitkus**, EFLM Awards & Grants Committee Chair

---



The EFLM Scientific Research Grant has been established to promote science and facilitate laboratory medicine research in Europe. Two grants of €10.000 each are awarded each year, one to an applicant from a country participating in the “Vic Blaton” scholarship program and the other to an applicant from any other European country. Applicants must submit a research project proposal and a detailed budget listing all required materials for their study.

For the 2026 EFLM Grant, we received 21 applications from 16 different countries. Applications were evaluated by a newly established EFLM Technical Committee “Awards & Grants” under the EFLM Division “Science: Value-Based Laboratory Medicine”, chaired by Assoc. Prof. Dalius Vitkus (Lithuania) and its members Prof. Antonio Buño Soto (Spain), Prof. Mariam Klouche (Germany), Prof. Klaus P. Kohse (Germany), and Prof. Katell Peoc’h (France). Final scores were also endorsed by the Chair of the EFLM Division “Science: Value-based Laboratory Medicine”, Prof. Michel Langlois. The evaluation process was conducted in accordance with the criteria established by the EFLM Executive Board. Evaluation included scoring of research project design, feasibility, budget justification by the research aims and methods, how innovative the research project is, potential of the research project to generate relevant findings in laboratory medicine, including improvement of patient outcome, relevance of previous work of the applicant to the proposed research based on the papers listed by the author in the Grant application, and scientific and professional experience of the applicant. Based on the listed criteria, the selected applications for the EFLM Scientific Research Grant 2026 are:

- **William van Doorn**, The Netherlands “AI-supported generation of interpretative comments for anemia diagnostics”;
- **Marija Sarić Matutinović**, Serbia (Vic Blaton Grant) “Unravelling the clinical utility of pro-resolving mediators in patients with Autoimmune Thyroid Diseases and Graves’ orbitopathy”.

Given the very small point gap among the top-ranked applicants, EFLM Technical Committee “Awards & Grants” extends congratulations to all participants who submitted high-quality, innovative study applications for the EFLM Research Grant 2026! We strongly encourage young scientists to continue applying for EFLM Grants in the coming years.

Let’s know more about the selected research.

---

## AI-supported generation of interpretative comments for anemia diagnostics

**William van Doorn**, Department of Clinical Chemistry, Central Diagnostic Laboratory, Maastricht University Medical Centre+, Maastricht, The Netherlands

---



Anemia diagnostics is one of the most frequently requested laboratory trajectories, yet interpreting combined hematology, iron status, and related biomarkers can remain complex for many clinicians. To support clinical decision-making, clinical chemists regularly add written interpretative comments to anemia panels. These comments improve diagnostic

efficiency and reduce unnecessary testing, but they are not standardized, vary between specialists, and are not digitally safeguarded.

Recent advances in machine learning suggest that models may be able to support complex reasoning tasks when thoughtfully embedded in clinical workflows. Our group has gained experience applying machine learning in acute care settings, which has shaped our understanding of both the potential and the limitations of these approaches. This project builds on those lessons by focusing specifically on anemia interpretation — using it as a feasible and clinically relevant test case to develop an AI-supported interpretative framework that is responsible and explainable.

Our study has three main aims: (1) to analyze reasoning patterns in anemia consults written by clinical chemists, (2) to develop and evaluate an AI model that generates draft interpretative comments, and (3) to assess accuracy, consistency, and usability among clinical chemists. We hypothesize that even with a modest dataset and a tightly scoped diagnostic domain, it is possible to generate useful AI-supported interpretative comments that improve consistency and reduce variability, while maintaining medical oversight.

We will retrospectively collect anemia consults from the laboratory at the Maastricht University Medical Centre+. Using systematic qualitative coding, we will extract key decision patterns including indices of iron deficiency, chronic disease markers, hemolysis markers, red cell indices, confounders such as renal disease and inflammation, and follow-up recommendations. Two recent language models suitable for medical text generation will be evaluated at baseline and after fine-tuning using the labeled consults, alongside a simple rule-based baseline. An expert panel of clinical chemists and a hematologist will then evaluate AI-generated consults on correctness, clinical usefulness, clarity, and need for editing, and compare them with historical human-written consults.

We hope to deliver a first step toward a validated AI-supported interpretative framework for a single high-volume diagnostic trajectory. Importantly, the model, prompts, and evaluation framework will be made openly available to the laboratory medicine community, enabling other institutions to test, adapt, and validate the approach in their own settings. The resulting prototype is deliberately scoped small for feasibility and clear impact, but designed to be reproducible and potentially scalable to other diagnostic trajectories in the future.

This project aims to support safer, more consistent diagnostic interpretation and to contribute to broader efforts on interpretative commenting across European laboratories — in line with EFLM priorities in diagnostic harmonization and responsible AI adoption.

**Thanks to the support of the EFLM Research Grant 2026, we look forward to exploring whether this approach can make a meaningful contribution to everyday laboratory practice.**

# Unravelling the clinical utility of pro-resolving mediators in patients with Autoimmune Thyroid Diseases and Graves' orbitopathy

Marija Sarić Matutinović, PhD, Department of Medical Biochemistry, Faculty of Pharmacy – University of Belgrade



Autoimmune thyroid diseases (AITD) are the most common thyroid disorders, affecting approximately 5% of the global population, significantly impairing patients' quality of life and imposing a substantial burden on healthcare systems (1, 2). These chronic conditions include Graves' disease (GD) and Hashimoto's thyroiditis (HT) that require lifelong therapy and surgical interventions, necessitating

advancements in laboratory diagnostics and treatment (3). Graves' orbitopathy (GO) is an inflammatory disease of the orbit and the most frequent extrathyroidal manifestation of GD. It is a debilitating and potentially sight-threatening disease that remains a unique pathophysiological and therapeutic enigma (4). Current therapeutic options are frequently limited by substantial adverse effects, and approximately one third of patients fail to achieve an adequate response to treatment. Both AITD and GO are multifactorial and considered to develop as a result of joint interaction of genetic predisposition, endogenous, and environmental factors.

However, despite extensive research, the etiopathogenesis of both AITD and GO remains incompletely understood and sensitive diagnostic and prognostic biomarkers are well needed (5, 6).

Persistent, non-resolving inflammation is a central feature of both AITD and GO, suggesting an imbalance between pro-inflammatory pathways and endogenous mechanisms that promote resolution (7). Specialized pro-resolving mediators (SPMs) are bioactive lipid mediators derived from polyunsaturated fatty acids that actively regulate initiation and termination of inflammation (8, 9). However, their role in AITD and GO has not yet been sufficiently explored (10). We hypothesize that dysregulated SPM pathways are associated with distinct AITD and GO phenotypes and that comprehensive SPM profiling could identify biomarkers of

disease activity and early treatment responsiveness. The aims of this study are to evaluate the clinical utility of SPM profiles in AITD and GO and to develop a comprehensive biomarker panel to better characterize immune activity in AITD and GO, and to identify high-risk patients prone to severe GO profile or treatment resistance.

Our preliminary findings demonstrated a significant association of plasma fatty acid composition and cholesterol metabolism alterations with the development of a more severe phenotype of GO. We propose that the imbalances of the lipid metabolic pathways play a significant role in the pathophysiology of AITD and GO, suggesting a new potential target for metabolic modulation and therapeutic intervention (11).

We will analyze the content of SPMs (maresins, resolvins, lipoxins, prostaglandins, leukotrienes) in patients' sera, using an "in-house" LC-MS/MS method. We will explore their association with the phenotype of disease, significant clinical parameters and thyroid biomarkers, aiming to identify disease- and phenotype-specific SPM signatures with clinical utility for early diagnosis, disease monitoring, and prediction of treatment response in AITD and GO. Sex will be incorporated as a biological variable to explore sex-related differences in SPM profiles, which may contribute to variability in disease presentation and therapeutic outcomes. The resulting biomarker panel is expected to correlate with disease phenotype and/or treatment response, supporting more personalized patient management. In the context of emerging therapies targeting inflammatory pathways in AITD and GO, SPM profiling may also serve as a tool for monitoring biological treatment effects. From a healthcare system perspective, translation of advanced lipid mediator profiling into clinical practice may reduce diagnostic delays, unnecessary interventions, and healthcare costs, while opening new avenues for resolution-based prevention and therapy. Scientifically, the findings of this study might provide a comprehensive insight into resolution pathways in AITD and GO, advancing understanding of chronic inflammation in endocrine autoimmunity.

## Literature:

1. Petranović O, Ovčariček P, Gorges R, Giovanella L. Autoimmune Thyroid Diseases. *Semin Nucl Med.* 2024;54:219-236.
2. Møllehave LT, et al. Trends in Costs of Thyroid Disease Treatment in Denmark during 1995-2015. *Eur Thyroid J.* 2018;7:75-83.
3. Bartalena L, Piantanida E, Gallo D, Ippolito S, Tanda ML. Management of Graves' hyperthyroidism: present and future. *Expert Rev Endocrinol Metab.* 2022 Mar;17(2):153-166. doi:10.1080/17446651.2022.2052044.
4. Bartalena L, Tanda ML. Current concepts regarding Graves' orbitopathy. *J Intern Med.* 2022;292:692-716.
5. Bartalena L, et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. *Eur J Endocrinol.* 2021;185:G43-67.
6. Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy. *Front Endocrinol (Lausanne).* 2020 Nov 30;11:615993. doi:10.3389/fendo.2020.615993.
7. Fallahi P, et al. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy. *Front Endocrinol (Lausanne).* 2021;12:654473
8. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. *Nature.* 2014;510:92-101. doi:10.1038/nature13479.
9. Julliard WA, Myo YPA, Perelas A, Jackson PD, Thatcher TH, Sime PJ. Specialized pro-resolving mediators as modulators of immune responses. *Semin Immunol.* 2022 Jan;59:101605. doi:10.1016/j.smim.2022.101605.
10. Song J, Sun R, Zhang Y, Fu Y, Zhao D. Role of the Specialized Pro-resolving Mediator Resolvin D1 in Hashimoto's Thyroiditis. *Exp Clin Endocrinol Diabetes.* 2021 Nov;129(11):791-797. doi:10.1055/a-1345-0173.
11. Sarić Matutinović M et al. Analysis of Non-Cholesterol Sterols and Fatty Acids in Patients with Graves' Orbitopathy: Insights into Lipid Metabolism in Relation to the Clinical Phenotype of Disease. *J Endocrinol Invest.* 2025. doi:10.1007/s4

## NEWS FROM THE EFLM FUNCTIONAL UNITS

### A call for action toward harmonization in laboratory medicine

A report from the EFLM Committee: Harmonisation

Reported by **Martina Zaninotto**, C-H Chair

Harmonization of laboratory reports is a continuous challenge for laboratory professionals. The harmonization of measurement units, reference intervals, and nomenclature/ terminology, the three key factors characterizing laboratory reports, must be achieved by sharing and adopting the recommendations as well as by following the suggestions by guidelines of the National and International Societies (1). The widespread acceptance of this approach is imperative, not only because harmonization of nomenclature and measurement units allow to minimize risk to patient safety but also considering the future "European Health Data Space" which will entail mandatory the accessibility and exchange of healthcare data. A recent survey carried out by EFLM Committee: Harmonisation C:H, (2) demonstrated that the community of the laboratory professional seriously underestimates the problem: some countries in Europe expressed little interest in this specific topic and 25 % of the countries failing to participate. In addition, although the data showed an overall and progressive, albeit slow, improvement in harmonization of reports provided by clinical laboratories in Europe (+13% in comparison to 2016), the real message arising from the data is that there is an urgent need for a change in attitude from all stakeholders involved in this process. In order to adopt a sustainable, possibly fast and promising approach, C:H identified and shared with EFLM community, particularly with "Division of Quality, Science and Value-based laboratory medicine" Chair and all Chairs of the related committees, some essential practical steps that should be adopted (3); -strongly encourage EQA scheme providers to use only SI units in reporting results. EQA performance represent a fundamental prerequisite for ISO 15189 accreditation, and, according to the proposed strategy, laboratories should adopt the SI units to evaluate their analytical performance through the EQA scheme; involve National accreditation bodies and metrology institutes, as the requirement to report results in SI units is part of the accreditation process; -persuade firmly the manufacturers (within the IVDR regulation) to exclusively include in their Instructions For Use (IFU), the SI units in product description, in declaring the specific analytical performance and in reporting the proposed reference intervals. Currently, in the IFU of the main manufacturers of reagents and systems, SI units are reported in brackets or named as "alternative" to the traditional units, the latter being identified as principal or "standard" units.

In addition, a webinar organized by EFLM planned and carried out by C:H members was recently held (February 10, 2026), aiming to raise awareness of the need for harmonisation, particularly urgent in terms of the measurement units in reporting results, given the imminent implementation of the European Health Data Space as

well as to share the strategies that should be adopted to achieve the goals. During the webinar, the speakers have reported on the most important issues of the main topic and in particular: -Prof. Luisa Agnello (Institute of Clinical Biochemistry, Clinical Molecular Medicine and Clinical Laboratory Medicine, University of Palermo, Italy) described the "State-of art of the post-analytical phase harmonization in European Laboratories" updating, in addition, on the results of a recent survey promoted by C: H on "Current practices and harmonisation challenges in Alzheimer's Disease Biomarkers"; -Prof. Lora Dukic (Clinical Department of Laboratory Diagnostics, Clinical Hospital Center Rijeka, Croatia) discussed the " Framework for adoption of SI measurement units in laboratory results reports" focusing on the relevance of the harmonization in terminology and units, stressing the criticisms potentially originating from the adoption of NPU and LOINC codes systems in different countries in Europe; -Prof. Leila Akhvlediani ( Shota Rustaveli State University, Lab of "Maritime Medical Centre 2010", Georgia) presented the pragmatic approach deals with " Sharing the strategy: stakeholders and clinical scientific societies involved", describing, among other things, the challenge of creating stakeholder engagement strategies for laboratory harmonization.

A further step in C:H activity will be the participation at the EFLM Strategic Conference 2026 in Prague, in the Session: "Harmonisation – the role of EFLM", during which the Chair of C:H, Martina Zaninotto (University of Padua, Italy), will give the presentation "What is the present role of EFLM in the harmonisation work" The purpose of this session, that include several presentations and a Round Table from different stakeholders, will be to describe the current harmonisation and standardisation initiatives in laboratory medicine in Europe and to develop a shared strategy for identifying which activities the EFLM should prioritise.

#### References

- 1) Hansen YBL. Recommendations on Measurement Units - Why and How. *EJIFCC*. 2019; 30: 250-275.
- 2) Zaninotto M, Agnello L, Dukic L, Akhvlediani L, on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group on Harmonization. Assessing post-analytical phase harmonization in European laboratories: a survey promoted by the EFLM Working Group on Harmonization. *Clin Chem Lab Med* 2024; 62:1966–74.
- 3) Zaninotto M, Agnello L, Dukic L, Šálek T, Linko-Parvinen A, Kalaria T, Vermeersch P on behalf of European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Committee-Harmonization (C-H) and Committee -Postanalytical Phase (C-POST). Is it feasible for European laboratories to use SI units in reporting results? *Clin Chem Lab Med* 2025; 63:1279-1285



The EFLM Committee on Harmonisation at EuroMedLab Congress 2025 in Brussels

Luisa Agnello (Palermo)  
Lora Dukic (Croatia)  
Martina Zaninotto (Padova)  
Leila Akhvlediani (Georgia)

To know more about the C-H and its current Members, please visit:

<https://www.eflm.eu/site/who-we-are/divisions/science-division/fu/c-harmonisation>

# Explore the updated 2026 EFLM Biological Variation Database

## Faster, Smarter, Easier Access!

---

### A New Look for the EFLM Biological Variation Database

Reported by the EFLM Technical Committee for the Biological Variation Database and the EFLM Committee Biological Variation

---

A new version of the EFLM Biological Variation Database, the main tool for access to quality-assessed biological variation data, has recently been published. The new database, which is available at [www.biologicalvariation.eu](http://www.biologicalvariation.eu) as well as via the EFLM homepage, delivers an improved look and feel to be experienced by users in 2026. The website functionality has been updated to enhance user access to over 3250 biological data sets extracted from close to 600 published articles reporting biological variation data. Furthermore, in the new version, users will easily identify quality-assessed biological variation minimum data sets, both for measurands where there is a meta-analysis published, as well as for measurands, in which there is not sufficient data to quality for a meta-analysis.


In the EFLM Biological Variation Database, all the included publications with different measurands and subgroup studies are assessed against the Biological Variation Data Critical Appraisal Checklist (BIVAC). The approach developed by the EFLM Biological Variation Groups enables data sets to be published on-line accompanied by indicators of graded compliance of the source publications with the 14 quality indicators identified in BIVAC. This is important as estimates of within- (CVI) and between-subject (CVG) biological variation are a form of reference data. The collated data within the EFLM database are therefore accompanied by a biological variation minimum data set to enable easy access of users to the essential high-level information required for initial assessment of the transportability and application of estimates into their clinical practice. The web entry also includes references to source publications to enable the user to undertake a more detailed assessment of veracity of the data and to assess its applicability to their local population. Where multiple publications of biological variation data exist for a particular measurand, the site delivers global estimates of biological variation derived from meta-analyses of BIVAC compliant publications. There are currently more than 190 meta-analysis derived global biological variation estimates published on the site, each delivering improved point estimates with tighter confidence limits, automatically derived

analytical performance specifications (APS) employing approaches that reflect latest thinking and the functionality to enable calculation of relevant reference change values (RCV).

The main driver for delivery of the current web site arose from the EFLM 1st Strategic Conference in Milan in 2014 where concerns were raised about the quality of the then available biological variation data to be used for the definition of APS. Building on the initial work of the EFLM Biological Variation Working Group various experts coming together from Europe and beyond have been involved in subsequent EFLM task/working groups and committees to focus upon the issues identified; their work has enabled quality and confidence issues around biological variation data to be identified and addressed. Checklists and guidance have been developed and delivered in the form of BIVAC and the more recently published Standard for Reporting Biological Variation Studies (STARBIV). These tools enable assessment of historical biological variation data and can be used to drive up the quality of future studies. It is notable that STARBIV is now listed on the EQUATOR network web site ([www.equator-network.org/reporting-guidelines/starbiv](http://www.equator-network.org/reporting-guidelines/starbiv)) including links to the STARBIV mind map published on the EFLM Biological Variation. This is of importance since EQUATOR is an international network initiative that is focussed upon enhancing the quality and transparency of health research promoting the use of well-established standards such as STARD. It is also notable that the Annals of Clinical Biochemistry, published by Sage Journals, now includes reference to STARBIV, in the reporting guidelines section of its current manuscript submission guidelines for authors.

In conclusion, the latest 2026 iteration of the EFLM Biological Variation Database web site makes available a rich source of critically assessed biological variation data, alongside tools, information and knowledge to support the safe and effective application of biological variation reference data by laboratory medicine specialists.

# FOUR SIMPLE ACTIONS TO BE MORE SUSTAINABLE AND GREEN IN YOUR LABORATORY!



## NEWS FROM THE EFLM FUNCTIONAL UNITS

### Four simple actions to be more sustainable and green in your laboratory!

Reported by **Tomris Ozben**, Chair of the EFLM Committee "Green & Sustainable Laboratories"

In line with the goal of the [EFLM Committee "Green & Sustainable Laboratories"](#), I have the pleasure to continue the column: Four simple actions to be more sustainable and green in your laboratory!

In each issue of the newsletter, we will select 4 actions from each section of the checklist prepared by the EFLM TF-GSL members (Chemicals, Energy, Waste and Water) to start implementing the daily routine in your laboratories and getting familiar with the checklist.

The below actions are accompanied by a graphical leaflet that you can download and post in the notice board of your laboratory to be shared with your colleagues (in this case, please remember to use recycled paper).

The selected actions of this issue are:

- Section "Hazardous Chemicals Management"**  
ACTION: Are computer simulations used instead of chemical reactions when possible?
- Section "Energy Management"**  
ACTION: Do you defrost freezers at least once a year?
- Section "Waste Management"**  
ACTION: Are obsolete computer equipment, printer toners, mobile phones, tablets & laptops recycled, sold or repurposed?
- Section "Water Management"**  
ACTION: Are awareness posters/stickers for water awareness visible throughout the lab?

[Click here to download the PDF](#)

WE ARE HAPPY TO INFORM YOU THAT 4 NEW LABORATORIES HAVE RECENTLY ACHIEVED THE CERTIFICATION, AND 2 LABORATORIES HAVE SUCCESSFULLY RENEWED THEIRS!

HAVE A LOOK AT THE LIST BELOW.



#### DENMARK

Translational Research Centre | Translational Research Centre, Rigshospitalet Glostrup  
Nordstjernevej 42 - Glostrup (2600) DENMARK  
Certificate issued on 2025-11-05 and valid till 2027-11-05.

NEW!



#### GERMANY

Labor Becker MVZ eGbR | Labor Becker MVZ eGbR  
Führichstraße 70 - München (81671) GERMANY  
Certificate issued on 2026-02-23 and valid till 2028-02-23.

NEW!



#### ITALY

Bianalisi - Laboratorio Generale | BIANALISI SpA  
Via Barzaghi 9 - Verano Brianza (MB) (20843) ITALY  
Certificate issued on 2025-11-19 and valid till 2027-11-19.

NEW!



#### POLAND

American Heart of Poland S.A. | American Heart of Poland S.A. Laboratoria Medyczne  
Al. Armii Krajowej 101 - Bielsko-Biała (43-316) POLAND  
Certificate issued on 2025-10-06 and valid till 2027-10-06.

NEW!



#### SWITZERLAND

labor team | labor team  
Blumeneggstrasse 55 - Goldach SG (9403) SWITZERLAND  
Certificate issued on 2026-02-24 and valid till 2028-02-24.



#### TURKIYE

Tıbbi Biyokimya Laboratuvarı | SBÜ Antalya Eğitim ve Araştırma Hastanesi  
Varlık Mahallesi, Kazım Karabekir Caddesi - Antalya (07050) TURKIYE  
Certificate issued on 2026-02-26 and valid till 2028-02-26.

The [EFLM "Green & Sustainable Laboratories" portal](#) is constantly open for applications!

This opportunity is available to any public or private laboratory specializing in: Clinical Chemistry, Hematology, Microbiology, Transfusion Services, Immunology, Pathology and Cytology.

If your certification has officially expired, but your commitment to sustainability is still strong, we invite you to log into your personal area from the link below and follow the instructions.

[Renew Your Certification Here](#)

*Keep Your Lab Green. Keep Your Legacy Growing!*

---

## EFLM YOUNG SCIENTISTS CORNER

# The EFLM Committee Young Scientist Networking Event one day ahead of the EFLM Strategic Conference 2026

Reported by **Aleksei Tikhonov**, Member of the EFLM Committee: Promotion & Publications, SFBC member

---

<https://www.eflm-strategic-conference2026.cz/eflm-committee-young-scientist-networking-event/>

---

DATE: 23 April 2026

---

TIME: 14:30–18:00

---

LOCATION: V Parku 2316/12, 148 00 Praha 11 – Chodov, Prague, Czech Republic

---

MAXIMUM NUMBER OF PARTICIPANTS: 40

---

REGISTRATION: [HERE](#) ↓

---

PRELIMINARY PROGRAM: [HERE](#) ↓

---

The EFLM Committee Young Scientist Networking Event, supported by Beckman Coulter, is an interactive, in-person event designed to support early-career laboratory professionals and researchers. Organised by the Committee for Young Scientists of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), the event takes place one day ahead of the EFLM Strategic Conference 2026 and offers a unique opportunity for focused discussion and networking. Participants will engage in small-group roundtable sessions led jointly by experienced representatives from EFLM and Beckman Coulter, covering key topics such as career development and employability, research and academia, leadership essentials, and communication and collaboration. The programme also includes welcome remarks, interaction with Arnold Beckman Award winners, and dedicated time for open networking. Participation is limited to 40 attendees to ensure meaningful exchange.



*Join us in Prague!*




## PAST EFLM EVENTS

### Past EFLM webinars on demand

Reported by **Aleksei Tikhonov**, member of the EFLM Committee: Promotion & Publications, SFBC member

**IMPORTANT:** A CERTIFICATE OF ATTENDANCE CAN BE DOWNLOADED DIRECTLY AT THE END OF THE WEBINAR AFTER THE SELF-LEARNING TEST IS SUCCESSFULLY COMPLETED



**Tumor markers; identifying pre-analytical, analytical and post-analytical challenges and opportunities to improve the clinical cancer care**

**SPEAKER:** Huub H. van Rossum (Netherlands) - Netherlands Cancer Institute




**Enhancing Risk Assessment Using Analytical Performance Insights**

**SPEAKER:** Leonor Guiñón (Spain) - Quality Director of Laboratories and the Extraction Service at the Hospital de la Santa Creu i Sant Pau in Barcelona.



**A call for action toward harmonization in laboratory medicine**

**SPEAKERS:** Luisa Agnello (Italy) - Dept BIND, Institute of Clinical Biochemistry, Clinical Molecular Medicine and Clinical Lab. Medicine, University of Palermo - Palermo, Italy; Leila Akhvlediani (Georgia) - Immunology Lab., Maritime Medical Centre, School of Medicine and Health Sciences, BAU International University - Batumi, Georgia; Lora Dukic (Croatia) - Clinical Dept. of Lab. Diagnostics, Clinical Hospital Center Rijeka - Rijeka, Croatia



**The role of copeptin in the investigation of AVP disorders**

**SPEAKER:** Chris Boot (UK) - Newcastle upon Tyne Hospitals NHS Foundation Trust



## UPCOMING EFLM EVENTS

### Forthcoming EFLM webinars

Reported by **Aleksei Tikhonov**, member of the EFLM Committee: Promotion & Publications, SFBC member

Do not miss excellent forthcoming webinars, free and available for EFLM Academy members at the EFLM e-learning platform! Watch live EFLM webinars and interact with experts.

**IMPORTANT:** A CERTIFICATE OF ATTENDANCE CAN BE DOWNLOADED FROM THE SECTION "PERSONAL AREA" OF THE PLATFORM STARTING FROM THE WORKING DAY FOLLOWING THE DATE OF EACH WEBINAR BY ALL THOSE PARTICIPANTS ATTENDING THE ENTIRE WEBINAR.



**Bone forming agents in osteoporosis: to split them or to lump them**

**Date:** 7th April 2026 at 18:00 (Brussels local time)

Important: make sure to accurately check the start time of the webinar in your local time zone. [Click here](#) to convert it.

**Speaker:** Jean-Yves Reginster (Saudi Arabia) - King Saud University, Riyadh, Kingdom of Saudi Arabia



**Reference Intervals versus Decision Limits and their specific qualities**

**Date:** 21st April 2026 at 18:00 (Brussels local time)

Important: make sure to accurately check the start time of the webinar in your local time zone. [Click here](#) to convert it.

**Speaker:** Thomas Streichert (Germany) - Professor, Institute for Clinical Chemistry, Central Laboratory | University Hospital Cologne (AöR)



**Bone Turnover Markers in CKD-associated Osteoporosis**

**Date:** 5th May 2026 at 13:00 (Brussels local time)

Important: make sure to accurately check the start time of the webinar in your local time zone. [Click here](#) to convert it.

**Speaker:** Samuel Vasikaran (Australia) - PathWest Laboratory Medicine – Western Australia, Perth, Australia



**Neurofilament Light Chain (NfL): The innovative biomarker in Multiple Sclerosis**

**Date:** 19th May 2026 at 18:00 (Brussels local time)

Important: make sure to accurately check the start time of the webinar in your local time zone. [Click here](#) to convert it.

**Speaker:** Loukia Psaridi (Greece) - Molecular Biologist - Clinical Biochemist. Head Director of Biochemistry Department Korgialeneio – Benakeio General Hospital of Athens



# EUROMEDLAB LONDON 2027



Association for  
Laboratory  
Medicine

## 27<sup>th</sup> IFCC-EFLM EUROMEDLAB CONGRESS OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

## LABMEDUK27 of the ASSOCIATION FOR LABORATORY MEDICINE

16-20 MAY 2027  
Excel London





## The EFLM Strategic Conference 2026 is approaching! Here is what you need to know

Reported by the EFLM Office

The countdown has begun for the **EFLM Strategic Conference 2026**, a key event for professionals in Laboratory Medicine and healthcare innovation. Taking place this spring in Prague, the conference will bring together experts, researchers, clinicians, and industry representatives to discuss the evolving role of Laboratory Medicine in modern healthcare systems. With an engaging scientific programme and opportunities for networking and collaboration, the meeting promises to be a stimulating platform for strategic dialogue on the future of the field.

The **EFLM Strategic Conference 2026** is held on **24–25 April 2026**, under the theme “Laboratory Medicine for Society.” The conference aims to address key developments and challenges in Laboratory Medicine while fostering discussion on priorities for the years ahead.

The conference will run over two full days with a dynamic scientific programme that includes keynote lectures, expert sessions and interactive discussions. The opening session on **Friday, 24 April** will begin at 09:00, followed by a keynote lecture on Value-based Laboratory Medicine. Sessions throughout the day will

explore topics such as harmonisation in Laboratory Medicine and the role of emerging technologies, including data-driven innovation and artificial intelligence. On **Saturday, 25 April**, the programme will focus strongly on cooperation with clinicians and international collaborations with European clinical associations, highlighting the importance of interdisciplinary partnerships in delivering effective patient care. Discussions will also address international cooperation, best practices across Europe, and the expectations of young scientists entering the field.

The event will be hosted at the **Vienna House Diplomat Prague**. The venue offers a modern conference centre with excellent facilities and convenient connections to both Prague Airport and the historic city centre.

### How to reach the venue

The conference venue is located in Prague’s diplomatic district of Dejvice and can be easily reached:

- From Václav Havel Airport Prague: approximately 15–20 minutes by taxi or public transport.
- By public transport: the nearby Dejvická metro station (Line A) provides a direct connection to Prague’s historic centre.
- By tram or bus: several lines connect the area with major transport hubs throughout the city.

### Accommodation offer

Participants can take advantage of conference accommodation options arranged by the organisers. Staying at or near the official venue ensures easy access to the meeting rooms and networking activities throughout the event. Availability may be limited, so participants are encouraged to reserve accommodation early. For availability and reservations, please contact the Organizing Secretariat – Alex Halasová at [halasova@cbttravel.cz](mailto:halasova@cbttravel.cz).

For further information regarding registration, accommodation or general enquiries, participants can contact the organising secretariat:

✉ Congress Business Travel | Email: [eflmprague2026@cbttravel.cz](mailto:eflmprague2026@cbttravel.cz)

### Sponsors and compliance

The Organisers extend their thanks to the conference sponsors whose support helps make the event possible. To know more, visit the dedicated [sponsors page](#) on the event website.

The EFLM Strategic Conference 2026 has also been approved as MedTech Europe compliant.

### CPECS CREDITS

The conference will provide continuing education opportunities through the EFLM Continuing Professional Education Credit System (CPECS®). A maximum of 13 CPECS credits can be awarded for participation in the educational sessions. Participants must attend at least 75% of each session and confirm their presence daily at the registration desk to qualify for credits. After the conference, eligible participants will receive an evaluation questionnaire and subsequently their CPECS certificate by email.

### NOT YET REGISTERED? DO IT NOW

Registration for the EFLM Strategic Conference 2026 is currently open. Participants can choose between in-person attendance or virtual participation, ensuring that the conference remains accessible to a global audience. The virtual attendance option provides access to all live sessions and conference materials, allowing participants to follow the programme remotely if they cannot travel to Prague.



Dear colleagues,

It is with great pleasure that we welcome the newly elected Regional Representatives to the IFCC Executive Board: Tomáš Zima, representing the European Federation of Clinical Chemistry and Laboratory Medicine, and Myrna Germanos, representing the Arab Federation of Clinical Biology. Moreover, we extend a warm welcome to the [new Chairs of the IFCC functional units](#) and we express our gratitude and appreciation to those who have concluded their tenure in office.

In her message, our President [Prof. Tomris Ozben](#) gives us valuable information about important IFCC meetings that ensure continuity of IFCC projects and initiatives, as well as will further strengthen the role of the IFCC as a global reference point in the field of laboratory medicine. She also invites us to register and participate in the XXVII IFCC WorldLab Congress, which will be held on 25-29 October 2026 in New Delhi, and will bring together healthcare professionals from all over the world.

The IFCC Awards Committee [calls for nominations for the IFCC Distinguished Awards](#) that will be presented at the IFCC WorldLab Congress New Delhi in October 2026. The closing date for receipt of nominations is 31 March 2026.

In this issue you can read an [interview of Professor Nader Rifai](#), IFCC President-Elect, and meet [Dr. Dusanka Kasapic](#), [Corporate Representative](#) for the IFCC Education and Management Division. You can also read about remarkable facts and remarks of the General Conference of IFCC, held in Bruges, Belgium, on May 16 and 17, 2025, which constituted a key strategic forum for the IFCC leadership, scientific leaders, representatives of full and affiliated member societies, regional federations, and corporate partners, greatly enhancing networking and fruitful collaboration among them.

Important news from the [IFCC Committee on Mobile Health and Bioengineering in Laboratory Medicine](#), the [IFCC-ISNS Joint Task Force on Global Newborn Screening](#), the IFCC WG-Ibero-American Nomenclature and Translations, the [IFCC Committee on Clinical Application of Cardiac Bio-Markers](#) and the [IFCC Professional Scientific Exchange Programme](#), are also included in this issue, highlighting their professional excellence, expertise, continuous development, innovation within complex healthcare environments, as well as their commitment on improving patient outcomes by the implementation of cutting edge technologies.

[News from the member societies](#) of Germany, Türkiye, Bolivia and Japan, confirm the commitment of these societies for high-performance, leadership and outstanding professional work. COLABIOCLI share with us their experience from ISO 15189 accreditation, thus showcasing their strong commitment to apply continuous improvement principles and to deliver high-quality medical laboratory services.

[UNIVANTS of Healthcare Excellence award program](#), awards integrated clinical care teams who achieve measurably improvements in healthcare. As evidenced by 2 of the top elite winners in association with the [UNIVANTS of Healthcare Excellence award program](#), accurate and timely triage of patients with a mild traumatic brain injury (mTBI) is paramount to patient safety and outcomes. There is growing momentum for blood brain biomarkers to aid in of mTBI patients in the emergency department. Interested in learning about the outcomes associated with biomarker-guided triage for mTBI, please visit [www.UnivantsHCE](http://www.UnivantsHCE). Applications for the [UNIVANTS of Healthcare Excellence award program](#) are accepted from August the 1st through November the 15th, 2026.

Under the theme "A Day at the Lab," the [IFCC Global Med Lab Week 2026](#) will be celebrated from April 20–26, 2026 and will underscore the significant contribution of the medical laboratory community to disease diagnosis, monitoring, prevention and follow up.

With warm regards,  
*Marilena Stamouli*  
IFCC eNews Editor

---

## Calendar of EFLM events and events under EFLM auspices

Do not miss the opportunity to have your event listed here.

Apply for EFLM auspices!

For more information visit [here](#) or email [eflm@eflm.eu](mailto:eflm@eflm.eu)

---



- >] | **EFLM Webinar**  
**Bone forming agents in osteoporosis: to split them or to lump them**  
on-line, 7 April 2026
- >] | **EFLM Webinar**  
**Reference Intervals versus Decision Limits and their specific qualities**  
on-line, 21 April 2026
- >] | **FSCC – 80 Years at the Heart of Laboratory Medicine**  
Helsinki (FI), 23-24 April 2026
- >] | **EFLM Strategic Conference 2026**  
**Laboratory Medicine for Society**  
Prague (CZ), 24-25 April 2026
- >] | **4th Azerbaijan Laboratory Medicine Congress & Lab Expo**  
Baku (AZ), 30 April - 2 May 2026
- >] | **EFLM Webinar**  
**Bone Turnover Markers in CKD-associated Osteoporosis**  
on-line, 5 May 2026
- >] | **The 17th International & 23rd National Congress on Quality Improvement in Clinical Laboratories**  
Tehran (IR), 5-8 May 2026
- >] | **1st IFCC Rome Forum – Paving the road for AI in Laboratory Medicine**  
Rome (IT), 11-12 May 2026
- >] | **XVIII Baltic Congress of laboratory Medicine**  
Riga (LV), 14-16 May 2026
- >] | **EFLM Webinar**  
**Neurofilament Light Chain (NfL): The innovative biomarker in Multiple Sclerosis**  
on-line, 19 May 2026
- >] | **17th Conference of the Romanian Association of Laboratory Medicine**  
Targu Mures (RO), 27-29 May 2026
- >] | **EFLM Webinar**  
**Accelerated diagnostic chest pain protocols; evidence and pitfalls in implementation**  
on-line, 9 June 2026
- >] | **LabMedUK26**  
Birmingham (UK), 8-10 June 2026

## Calendar of EFLM events and events under EFLM auspices

Do not miss the opportunity to have your event listed here.

Apply for EFLM auspices!

For more information visit [here](#) or email [eflm@eflm.eu](mailto:eflm@eflm.eu)



**EFLM Webinar**

**The role of angiogenetic factors in placental disorders**

on-line, 23 June 2026



**EFLM Webinar**

**Laboratory Insights into Neurological Disorders: Spinal Cord and Alzheimer's Disease – Challenges and Modern Perspectives**

on-line, 7 July 2026



**40th Nordic Congress in Clinical Biochemistry**

Aarhus (DK), 15-18 September 2026



**21th Congress of The polish Society for laboratory Diagnostics**

Białystok (PL), 16-19 September 2026



**International XXIV Congress of Medical Biochemistry and Laboratory Medicine**

Belgrade (RS) 23-25 September 2026



**7th Slovenian Congress of Clinical Chemistry and Laboratory Medicine with international participation**

Portorož (SI), 5-6 October 2026



**12th Congress of the Croatian Society of Medical Biochemistry and Laboratory Medicine with international participation**

Srebreno (HR), 15-18 October 2026



**The Second Congress of the Kosovo Association of Clinical Chemistry (KACC)**

Pristina (XK), 5-6 November 2026



**Annual Meeting of RBSLM**

Brussels (BE), 18-19 November 2026



**EuroMedLab 2027**

**27th European Congress of Clinical Chemistry and Laboratory Medicine**

**LABMEDUK27 of the Association for Laboratory Medicine**

London (UK) 16-20 May 2027

**EFLM**  
EUROPEAN FEDERATION OF CLINICAL CHEMISTRY  
AND LABORATORY MEDICINE

# EFLM Strategic Conference 2026

Laboratory Medicine for Society

**24 – 25 April 2026 Prague, Czech Republic**

<https://www.eflm-strategic-conference2026.cz>